- Nexalin Technology (NXL, Financial) secures USPTO patent for its Deep Intracranial Frequency Stimulation (DIFS™) technology.
- The patent covers a non-invasive, drug-free method for treating various Substance Use Disorders, including opioid, alcohol, and stimulant addictions.
- DIFS™ technology offers a promising alternative to conventional addiction treatments, potentially overcoming issues like accessibility and side effects.
Nexalin Technology, Inc. (NXL) has achieved a significant milestone by obtaining a patent from the United States Patent and Trademark Office (USPTO) for its innovative Deep Intracranial Frequency Stimulation (DIFS™) technology. The patent, titled "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD)," enhances Nexalin's intellectual property portfolio and underscores its commitment to leading the field of addiction treatment with a non-invasive and drug-free approach.
The newly patented DIFS™ technology is specifically designed to assist individuals struggling with substance use disorders, including opioid, alcohol, and stimulant dependencies. By applying deep-brain stimulation at dynamic frequencies, the technology aims to regulate neural pathways associated with addiction and withdrawal symptoms. This approach provides a potential alternative to traditional treatments like medication-assisted therapy (MAT), which often face challenges such as accessibility issues, pharmaceutical dependency, and side effects.
Mark White, CEO of Nexalin Technology, highlighted the importance of this patent, stating, "Securing this patent grant from the USPTO is a significant achievement for Nexalin as we continue to push the boundaries of non-invasive brain stimulation. Our DIFS™ technology has the potential to transform addiction treatment by addressing chronic relapse through targeted neuromodulation, potentially reducing anxiety, depression, and cravings that lead to relapse."
This development marks another step in Nexalin's mission to redefine care standards in addiction and mental health treatment. The company's expanding intellectual property portfolio, including this patent, positions it favorably in the competitive landscape where non-pharmaceutical approaches to addiction are increasingly in demand. While the patent does not guarantee immediate market success, it provides essential protection for future commercialization efforts, potentially opening doors to licensing opportunities and long-term shareholder value.
